Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
Identifieur interne : 000783 ( Pmc/Corpus ); précédent : 000782; suivant : 000784Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
Auteurs : Tony Velkov ; Nusaibah Abdul Rahim ; Qi Tony Zhou ; Hak-Kim Chan ; Jian LiSource :
- Advanced drug delivery reviews [ 0169-409X ] ; 2014.
Abstract
One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.
Url:
DOI: 10.1016/j.addr.2014.11.004
PubMed: 25446140
PubMed Central: 4429008
Links to Exploration step
PMC:4429008Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead</title><author><name sortKey="Velkov, Tony" sort="Velkov, Tony" uniqKey="Velkov T" first="Tony" last="Velkov">Tony Velkov</name><affiliation><nlm:aff id="A1">Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</nlm:aff></affiliation></author><author><name sortKey="Rahim, Nusaibah Abdul" sort="Rahim, Nusaibah Abdul" uniqKey="Rahim N" first="Nusaibah Abdul" last="Rahim">Nusaibah Abdul Rahim</name><affiliation><nlm:aff id="A1">Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</nlm:aff></affiliation></author><author><name sortKey="Zhou, Qi Tony" sort="Zhou, Qi Tony" uniqKey="Zhou Q" first="Qi Tony" last="Zhou">Qi Tony Zhou</name><affiliation><nlm:aff id="A2">Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia</nlm:aff></affiliation></author><author><name sortKey="Chan, Hak Kim" sort="Chan, Hak Kim" uniqKey="Chan H" first="Hak-Kim" last="Chan">Hak-Kim Chan</name><affiliation><nlm:aff id="A2">Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia</nlm:aff></affiliation></author><author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name><affiliation><nlm:aff id="A1">Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25446140</idno><idno type="pmc">4429008</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429008</idno><idno type="RBID">PMC:4429008</idno><idno type="doi">10.1016/j.addr.2014.11.004</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000783</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000783</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead</title><author><name sortKey="Velkov, Tony" sort="Velkov, Tony" uniqKey="Velkov T" first="Tony" last="Velkov">Tony Velkov</name><affiliation><nlm:aff id="A1">Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</nlm:aff></affiliation></author><author><name sortKey="Rahim, Nusaibah Abdul" sort="Rahim, Nusaibah Abdul" uniqKey="Rahim N" first="Nusaibah Abdul" last="Rahim">Nusaibah Abdul Rahim</name><affiliation><nlm:aff id="A1">Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</nlm:aff></affiliation></author><author><name sortKey="Zhou, Qi Tony" sort="Zhou, Qi Tony" uniqKey="Zhou Q" first="Qi Tony" last="Zhou">Qi Tony Zhou</name><affiliation><nlm:aff id="A2">Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia</nlm:aff></affiliation></author><author><name sortKey="Chan, Hak Kim" sort="Chan, Hak Kim" uniqKey="Chan H" first="Hak-Kim" last="Chan">Hak-Kim Chan</name><affiliation><nlm:aff id="A2">Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia</nlm:aff></affiliation></author><author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name><affiliation><nlm:aff id="A1">Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">Advanced drug delivery reviews</title><idno type="ISSN">0169-409X</idno><idno type="eISSN">1872-8294</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P2">One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8710523</journal-id><journal-id journal-id-type="pubmed-jr-id">21484</journal-id><journal-id journal-id-type="nlm-ta">Adv Drug Deliv Rev</journal-id><journal-id journal-id-type="iso-abbrev">Adv. Drug Deliv. Rev.</journal-id><journal-title-group><journal-title>Advanced drug delivery reviews</journal-title></journal-title-group><issn pub-type="ppub">0169-409X</issn><issn pub-type="epub">1872-8294</issn></journal-meta><article-meta><article-id pub-id-type="pmid">25446140</article-id><article-id pub-id-type="pmc">4429008</article-id><article-id pub-id-type="doi">10.1016/j.addr.2014.11.004</article-id><article-id pub-id-type="manuscript">NIHMS642182</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Velkov</surname><given-names>Tony</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Rahim</surname><given-names>Nusaibah Abdul</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Qi (Tony)</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Hak-Kim</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia, Parkville, Victoria, Australia</aff><aff id="A2"><label>b</label>Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia</aff><author-notes><corresp id="FN1"><label>*</label>Corresponding author: Jian Li, Phone: +61-3-9903-9702; Fax: +61-3-9903-9583; <email>colistin.polymyxin@gmail.com</email></corresp><fn id="FN2" fn-type="conflict"><p><bold>Conflict of interest</bold></p><p>The authors declare no competing financial or otherwise conflicts of interest with respect to the content of this review.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>13</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>12</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>5</month><year>2016</year></pub-date><volume>85</volume><fpage>65</fpage><lpage>82</lpage><pmc-comment>elocation-id from pubmed: 10.1016/j.addr.2014.11.004</pmc-comment>
<permissions><copyright-statement>© 2014 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2014</copyright-year></permissions><abstract><p id="P2">One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.</p></abstract><kwd-group><kwd>Inhalation</kwd><kwd>antibiotics</kwd><kwd>antivirals</kwd><kwd>antifungals</kwd><kwd>pharmacokinetics/pharmacodynamics</kwd><kwd>safety</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000783 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000783 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:4429008
|texte= Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:25446140" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |